Given the commercial scale of the obesity market, AstraZeneca is one of several large pharma players betting that the oral delivery format will be the dominant paradigm within a decade
There are several GLP-1RAs and one GIP/GLP-1RA available for the management of T2DM and/or obesity
Together, these developments are reshaping how we think about modifying disease and point to a future with more durable, biologydriven solutions. This years lineup of late-breaking clinical trial sessions includes: June 5 Amylin as a Novel Diabetes and Obesity Therapy Dual Agonism in Type 1 Diabetes: Unveiling Efficacy and Safety of Adjunct Therapy with CT-868 (GLP-1/GIP RA) in Adults with Type 1 DiabetesPhase 1 and 2 Results June 6 The VESPER-1 OLE, -2 and -3 Trials of Berobenatide (MET-097, PF-08653944) an Ultra-Long-Acting GLP-1 Receptor Agonist for Weight Management Unlocking the Next Frontier in Treatment of Obesity and Type 2 Diabetes with Restitutive: A Triple Agonist, Activating the GIP, GLP-1 and Glucagon Receptors (TRANSCEND-T2D-1 and TRIUMPH-1 Results) June 7 The AIDING Trial: Automated Insulin Delivery in the HospitalResults and Implications for Inpatient Diabetes Care REIMAGINE 1, 2, 3: Leveraging Amylin and GLP-1 for Type 2 Diabetes Care with CagriSema The Benefits of Glucagon/GLP-1 Receptor Dual Agonism: Insights from the SYNCHRONIZE Phase 3 Studies of Survodutide June 8 From Pen to Pill: Achieving a Paradigm Shift in Type 2 DiabetesThe Orforglipron ACHIEVE Clinical Trial Program AZD5004, A Novel Oral Small Molecule GLP-1 Receptor Agonist: Overweight/Obesity (VISTA) and Type 2 Diabetes (SOLSTICE) Phase 2 Trial Results The significant progress were seeing in clinical trials was largely driven by decades of foundational basic science research, much of which was presented at past ADA Scientific Sessions, Dr
They also aid in reducing inflammation and oxidative stress, supporting overall well-being
Hydrodynamic dimensions of IDPs can be studied by SEC as well
